Chronicling the COPD Patient Journey and Change in Impact of a Single Inhaler Combination Therapy on COPD Symptoms, Quality of Life and Exacerbations Following Initiation of Budenoside/Glycopyrronium/Formoterol [BGF](CHRONICLES COPD)
Latest Information Update: 09 Feb 2026
At a glance
- Drugs Budesonide/formoterol/glycopyrrolate (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Acronyms CHRONICLES COPD
- Sponsors AstraZeneca
Most Recent Events
- 04 Feb 2026 Planned End Date changed from 31 Mar 2026 to 20 May 2026.
- 04 Feb 2026 Planned primary completion date changed from 31 Mar 2026 to 20 May 2026.
- 02 Dec 2025 Status changed from recruiting to active, no longer recruiting.